Adipotide Peptide: The Complete Guide - Uses, Mechanism, Dosing, Safety & Research

Quick Facts

What Adipotide Does & How It Works

What It Does , Functional Outcomes

Adipotide's documented effects in animal research are distinct from every other compound in the research peptide space. Here is what the evidence shows it does:

• Reduces white adipose tissue volume - the primate study documented a 27-39% reduction over approximately four weeks
• Reduces total body weight proportional to fat mass lost - approximately 11% in the primate study
• Preferentially targets visceral fat depots, which are associated with the highest metabolic risk
• Improves insulin sensitivity - substantially, as measured by HOMA-IR and glucose tolerance in the primate study
• Reduces serum triglycerides
• Preserves lean body mass - fat loss in the primate study was selective, with no significant reduction in muscle mass

None of these outcomes have been documented in human beings in a controlled setting. Every data point above comes from animal research.

How It Works , Mechanism of Action

This is where Adipotide earns the attention it has received in research circles. The mechanism is genuinely unlike anything else studied for fat loss.

Step 1 - Targeted Homing via Prohibitin Binding (Evidence: Animal and ex vivo human tissue)

After subcutaneous injection, Adipotide circulates through the bloodstream. The CKGGRAKDC targeting domain selectively binds to prohibitin - a protein that is expressed on the luminal surface of blood vessels supplying white adipose tissue at substantially higher levels than on the vascular endothelium of other organs. This differential expression is the entire basis of the compound's selectivity.

Step 2 - Cellular Internalization and Mitochondrial Disruption (Evidence: In vitro and animal)

Once the targeting domain binds prohibitin, the entire compound is internalized into the endothelial cells lining the fat-feeding blood vessels. Inside those cells, the D(KLAKLAK)2 effector domain reaches the mitochondria and disrupts mitochondrial membrane integrity. This triggers the intrinsic apoptotic cascade - programmed cell death initiated from inside the cell.

Step 3 - Vascular Regression and Adipocyte Death (Evidence: Animal - rodent and primate - Barnhart et al., 2011)

Death of endothelial cells causes the blood vessels themselves to regress and collapse. Without a blood supply, the adipocytes - the fat cells - in affected depots are cut off from oxygen and nutrients. They undergo ischemic death and are cleared by the immune system over subsequent days to weeks. The fat mass is reduced not by shrinking fat cells or preventing fat storage, but by eliminating the cells themselves through the destruction of their support infrastructure.

Adipotide Molecular Profile

Structure reference: View Adipotide on PubChem - Publishing team: retrieve 2D structure image from this link.

Adipotide Uses & Benefits

Investigational Obesity Treatment

Adipotide was developed specifically as an investigational approach to obesity treatment, targeting a mechanism entirely distinct from the appetite-suppression and metabolic approaches that define most other fat-loss compounds. The rationale is straightforward: white adipose tissue is heavily dependent on its blood supply, and that blood supply has molecular signatures - specifically prohibitin expression on the vessel surface - that other tissue vasculature largely lacks. By targeting and destroying that vasculature, the compound eliminates fat depots directly rather than relying on metabolic changes or reduced caloric intake. The primate study demonstrated that this approach works in a metabolically relevant animal model, producing 27-39% reductions in white adipose tissue volume over four weeks. (Evidence: Preliminary - animal only - Barnhart et al., 2011)

Visceral Fat and Metabolic Risk Reduction

A secondary but clinically significant finding from the primate research was that visceral fat - the fat stored around abdominal organs that carries the highest association with metabolic disease, insulin resistance, and cardiovascular risk - appeared preferentially reduced in treated animals. The metabolic improvements observed alongside the fat loss (improved insulin sensitivity, reduced triglycerides) were attributed primarily to the removal of this metabolically active visceral fat rather than to any direct metabolic action of the peptide itself. For researchers studying metabolically driven obesity and its complications, this aspect of the mechanism is of particular interest. (Evidence: Preliminary - animal only - Barnhart et al., 2011)

Research Into Vascular Biology of Adipose Tissue

Beyond its potential as a therapeutic agent, Adipotide and its components have served as tools for understanding the molecular biology of adipose tissue vasculature. The discovery that prohibitin is expressed on the luminal surface of fat-feeding blood vessels - accessible to circulating peptides - opened a research direction into how white adipose tissue vascular beds differ at a molecular level from other vascular beds. This line of inquiry has implications beyond obesity, touching on tumor-associated adipose tissue, fat tissue remodeling in metabolic disease, and the biology of weight regain after fat loss. (Evidence: Animal and ex vivo human tissue - Kolonin et al., 2004)

Community Use for Fat Loss Protocols

Despite the absence of human clinical data and the documented kidney toxicity concern from the primate study, Adipotide has found a presence in gray-market research peptide communities. Users in these communities report using it for general fat loss and body composition improvement, often in conjunction with other peptides or compounds. These reports are anecdotal, uncontrolled, and carry no clinical validation. The community use pattern is documented here as factual context - not an endorsement of or guidance toward self-administration. (Evidence: Anecdotal / community-reported)

Where This Guide Comes From

Adipotide Results & Timelines

The timeline picture for Adipotide is unusual because the primary reference point is a single controlled primate study rather than a body of human clinical data. What follows represents a synthesis of what the published research documented and what users in community protocols have reported - attributed distinctly so the difference in evidence quality is clear.

Fat Mass Reduction and Body Composition

• Week 1-2: The primate research does not characterize early-stage responses in detail; MRI measurements were taken at baseline and endpoint rather than at intermediate points. Community reports suggest limited visible change in the first two weeks, consistent with the biological timeline of vascular regression and adipocyte clearance.
• Week 3-4: The primate study's endpoint measurements - 27-39% fat volume reduction and approximately 11% body weight reduction - were recorded at approximately four weeks. Community reports note this as the window where effects, if they are occurring, become more apparent.
• Beyond 4 weeks: No published data characterizes what happens with extended treatment beyond the approximately four-week study period. Community protocols extending to 6-8 weeks exist in forum documentation, but outcomes beyond four weeks are entirely unvalidated.

Metabolic Markers (Insulin Sensitivity, Triglycerides)

• End of treatment (~4 weeks): Improvements in HOMA-IR and glucose tolerance were documented at the study endpoint in the primate research. These improvements appeared correlated with the degree of fat mass lost rather than occurring independently.
• Timeline of onset: No intermediate measurements exist in the published research. Whether metabolic improvements precede, accompany, or follow the fat mass reduction is not characterized.

How to Administer Adipotide

Subcutaneous Injection (SubQ)

Subcutaneous injection is the only administration route used in published Adipotide research and the only route for which any efficacy or safety data exists. In both the rodent and primate studies, the compound was administered via SubQ injection. Systemic bioavailability via this route is sufficient to allow the compound to reach prohibitin-expressing vascular endothelium in fat depots throughout the body. Community protocols uniformly describe subcutaneous administration.

Intramuscular Injection (IM)

Intramuscular administration has not been studied for Adipotide in any published research. There is no pharmacokinetic or bioavailability comparison between IM and SubQ routes for this compound, and no basis in the literature for preferring IM delivery. Community documentation does not consistently describe IM administration as a standard route.

Oral

Oral administration of Adipotide is not viable. The compound is a peptide of approximately 2,630 Da with a chimeric structure that includes a disulfide-bridged targeting domain and D-amino-acid-modified effector domain. Even with the protease-resistant D-amino acid modifications in the effector domain, the compound would be substantially degraded by gastric acid and the digestive enzyme environment before reaching systemic circulation in concentrations sufficient to produce any effect. No oral formulation of Adipotide has been studied. All published research used parenteral administration.

Adipotide Dosage & Cycle Length

The dosing picture for Adipotide is unusual compared to most research peptides because the only controlled efficacy data comes from animal studies, and translating animal dosing to human use involves significant uncertainty under the best of circumstances. For Adipotide specifically, that translation carries the additional complication of a documented kidney safety concern that has not been resolved in any human population. The figures below represent what the published research used and what the research community has documented in practice - not a human dosing recommendation.

Overall dosing spectrum from published research: Approximately 1 mg/kg/day in the rhesus monkey study; 0.5-2 mg/kg/day range across rodent studies

Community-documented protocol range: 250-500 mcg per injection, administered once or twice daily - reported in gray-market research communities; not validated in human clinical data

How the goal context shifts where protocols land:

• Lower end of the community-reported range: 250 mcg per injection, once daily - more commonly referenced in longer exploratory protocols
• Mid range: 250-500 mcg once daily - the most frequently reported pattern in community protocol logs
• Higher end: Doses approaching 500 mcg twice daily appear in community discussions but carry the greatest extrapolated kidney concern given the primate findings

Frequency: Daily administration in the primate study; once or twice daily in community-reported protocols

Cycle length: Approximately 28 days (4 weeks) in the key primate research; 4-8 weeks referenced in community protocol documentation; no data exists on repeat cycling safety or appropriate off-cycle intervals

Loading protocols: No loading protocol has been documented in published research or established in community practice for Adipotide. The primate study used consistent daily dosing from day one.

An important framing note: The doses used in the rhesus monkey study that produced both the fat loss results and the kidney toxicity findings were approximately 1 mg/kg/day - a dose that, translated to human body weight, represents a substantially higher absolute amount than the 250-500 mcg figures circulating in community protocols. Whether lower community-reported doses produce meaningful efficacy, reduce kidney risk proportionally, or both remains entirely unknown. There is no dose-response data in humans, no minimum effective dose established for humans, and no safe dose established for humans.

Adipotide Vial Sizes, Costs & Quality

Common vial sizes: 2 mg, 5 mg, and 10 mg are the sizes most consistently available from research suppliers, with 2 mg and 5 mg being the most commonly encountered.

Typical cost range: Adipotide runs meaningfully higher per milligram than common research peptides like BPC-157 or TB-500, reflecting the complexity of synthesizing a chimeric construct with two functional domains, a specific disulfide bridge, and D-amino acid modifications. Expect roughly $80-$150 per 2 mg vial and $150-$280 per 5 mg vial from U.S.-manufactured research-grade sources at current market pricing - though prices vary significantly by supplier and quality tier.

Storage - lyophilized (dry powder):

• Temperature: Long-term storage at -20 degrees C; short-term storage at 2-8 degrees C is acceptable for up to a few weeks
• Shelf life: Up to 24 months from manufacture date when stored correctly at -20 degrees C; significantly shorter at refrigerator temperatures
• Light sensitivity: Protect from direct light; amber vials or foil-wrapped storage preferred

Storage - reconstituted (in solution):

• Temperature: Refrigerate at 2-8 degrees C once reconstituted; do not freeze reconstituted solution
• Use window: Typically 30 days once reconstituted, though stability data specific to Adipotide in solution is limited in the published literature; use within 2-4 weeks is the more conservative community practice

Normal appearance after reconstitution: Adipotide typically reconstitutes into a clear, colorless solution. The chimeric construct is soluble in standard reconstitution media. Any significant cloudiness or particulate matter after mixing and gentle swirling is not expected and warrants discarding the vial.

Signs of degradation: Heavy cloudiness that does not clear with gentle warming to room temperature, visible particulates or floating matter, yellow or brown discoloration, or any unusual odor. Degraded peptide should not be used.

Quality Considerations

Adipotide's synthesis complexity makes quality variation more consequential here than with simpler peptides. The compound requires correct construction of two separate functional domains, proper D-amino acid incorporation in the effector domain, and formation of the disulfide bridge between the two cysteine residues in the targeting domain - any failure at any of these steps produces a peptide that either does not work or does not work as intended. A vial that looks identical to a correctly synthesized product can contain a misfolded, incomplete, or entirely incorrect sequence, and you cannot tell the difference by looking at it. Third-party HPLC and mass spectrometry testing is not a nice-to-have for a compound this complex - it is the only meaningful quality verification available to a buyer. Overseas synthesis facilities with no independent testing requirement and no chain-of-custody accountability represent a significant unknown, particularly for a compound where the safety concern is already real and documented in controlled research. U.S.-manufactured research peptides come with documented synthesis standards, third-party testing, and verifiable certificates of analysis.

Adipotide Side Effects & Safety

Adipotide's safety profile is not a theoretical concern list assembled from first principles - it is a documented finding from controlled primate research. The kidney toxicity identified in the 2011 rhesus monkey study is the single most important piece of safety information about this compound, and it is the primary reason Adipotide has not advanced to human clinical trials. Everything else in this section is either extrapolated from that research or drawn from community-reported experiences that carry no clinical validation.

Side Effect Spectrum

Contraindications

• Existing kidney disease or impaired renal function: The documented nephrotoxicity in primate research represents a direct contraindication in anyone with compromised baseline kidney function. Even in the primate study, which used healthy animals, kidney markers were elevated and not fully reversed in all animals after treatment ended.
• Concurrent use of nephrotoxic medications: Combining Adipotide with other compounds that stress kidney function - including NSAIDs, certain antibiotics, contrast agents, or other nephrotoxic compounds - represents a compounding risk with no safety data.
• Active cancer: The mechanism targets vasculature expressing prohibitin, and the effects on tumor vasculature or cancer-associated adipose tissue are unknown and potentially unpredictable.
• Pregnancy and breastfeeding: Insufficient safety data exists; the mechanism involves programmed vascular cell death and has unknown implications for fetal or neonatal physiology.
• Prior allergic reactions to peptide therapeutics: The chimeric structure introduces immunogenic potential that simpler peptides may not carry.

Populations Where Caution Is Warranted

• Pregnancy and breastfeeding: Insufficient safety data; use is not recommended without medical supervision
• Pediatric use: Not studied in pediatric populations; not appropriate without medical supervision
• Anyone with a single kidney or prior kidney surgery: The nephrotoxicity concern is materially elevated in this population given reduced total kidney functional reserve
• Individuals with metabolic syndrome or type 2 diabetes: While the primate data showed metabolic improvement, individuals in this population are more likely to have baseline kidney function compromise that amplifies the nephrotoxicity risk

Red Flags , Stop Use and Seek Medical Attention If:

• Significant flank or lower back pain that is new or worsening
• Visible blood in urine or dark-colored urine
• Sudden reduction in urine output or frequency
• Unusual swelling, particularly in the legs or face
• Signs of systemic allergic reaction: facial swelling, difficulty breathing, rapid heart rate, widespread skin reaction

Drug and Compound Interactions

No formal drug interaction studies exist for Adipotide in any published literature - the compound has not progressed to the stage of pharmacokinetic interaction research. The primary interaction concern is additive nephrotoxicity from concurrent use of other kidney-stressing compounds. Theoretically, any agent that increases vascular permeability, promotes widespread apoptosis, or impairs renal clearance could compound the kidney risk documented in the primate study. Anti-angiogenic compounds used concurrently could produce additive vascular effects. No specific interaction data exists and none can be stated with confidence.

Adipotide Research & Studies

Adipotide has a research footprint that is small but meaningful. Two landmark papers - a 2004 mouse study and a 2011 non-human primate study - form the core of the published evidence. Several supporting papers characterize the prohibitin-targeting mechanism and validate the homing sequence. No human clinical trials have been published. What follows is an honest account of what the evidence shows, what it does not show, and where the critical gaps remain.

Pharmacokinetics & Metabolism

Absorption and Bioavailability Adipotide is administered subcutaneously in all published research, and systemic bioavailability via this route is sufficient to produce documented effects on fat vasculature throughout the body in animal models. The compound enters circulation after SubQ injection and distributes via the bloodstream to reach prohibitin-expressing vascular endothelium in adipose tissue. No direct measurement of bioavailability percentage has been published for Adipotide specifically.

Distribution Distribution studies in animal models demonstrate preferential accumulation of the CKGGRAKDC targeting domain in white adipose tissue vasculature compared to other tissue vascular beds including liver, kidney, muscle, and heart at therapeutic doses. However, the kidney toxicity findings in the primate study suggest that some off-target renal accumulation or indirect renal effects occur at doses sufficient to produce fat loss. Whether this represents direct peptide accumulation in renal tissue or secondary effects from large-scale fat tissue breakdown has not been fully resolved.

Half-Life A precise half-life for Adipotide has not been published in the available literature. The D-amino acid modifications in the KLAKLAK effector domain confer resistance to proteolytic degradation, which likely extends the functional half-life compared to an unmodified peptide of similar size. Daily dosing in both the rodent and primate studies suggests the effective duration of action does not extend across a full 24-hour period, but the specific pharmacokinetic parameters have not been directly measured and published.

Metabolism and Elimination Detailed metabolic and elimination pathway data has not been published for Adipotide. The compound is expected to be eliminated primarily through renal filtration and proteolytic breakdown over time. The kidney toxicity finding in the primate study raises the possibility that renal handling of the compound or its breakdown products contributes to the nephrotoxic effect, though this has not been mechanistically confirmed.

Mechanistic Research

Prohibitin as a Vascular Homing Target in Adipose Tissue (Evidence: Animal and ex vivo human tissue - Kolonin et al., 2004)

The identification of prohibitin as an accessible surface receptor on fat-feeding vascular endothelium came from phage display experiments conducted by Kolonin, Pasqualini, Arap, and collaborators. The CKGGRAKDC sequence was isolated as a peptide that specifically homes to white adipose tissue vasculature in vivo in mice. Subsequent validation demonstrated that prohibitin is the binding target and that this surface expression is substantially higher in fat vasculature than in the vascular endothelium of other organs. Importantly, prohibitin expression was also confirmed in human white adipose tissue vasculature in ex vivo studies, providing cross-species validation of the targeting mechanism's translational relevance.

Pro-apoptotic Mechanism of the D(KLAKLAK)2 Effector Domain (Evidence: In vitro and animal)

The D(KLAKLAK)2 domain is derived from an antimicrobial peptide sequence. In its D-amino acid form, it resists degradation by cellular proteases, extending its functional lifespan inside cells. Once internalized, it acts on mitochondrial membranes - disrupting membrane integrity in a way that triggers the intrinsic apoptotic cascade. Research on this domain demonstrates that it is relatively non-toxic systemically on its own because it requires receptor-mediated cellular internalization to reach mitochondria at effective concentrations. The targeting domain of Adipotide provides that internalization pathway specifically in prohibitin-expressing cells.

Vascular Regression Following Endothelial Apoptosis (Evidence: Animal - rodent and primate - Barnhart et al., 2011)

Studies in both rodent and primate models documented histological confirmation of endothelial apoptosis in white adipose tissue vasculature following Adipotide administration, followed by vessel regression and subsequent adipocyte death in affected fat depots. MRI imaging in the primate study visually confirmed the reduction in fat depot volume in a way that correlated with the histological findings. The structural nature of this outcome - actual reduction in fat cell number rather than just temporary cellular changes - is what distinguishes Adipotide mechanistically from all other fat-loss compounds studied to date.

Condition-Focused Research

Obesity and Fat Mass Reduction {#research-obesity}

The foundational study of Adipotide's efficacy was published in Science in 2004 by Kolonin and colleagues. Diet-induced obese mice received the chimeric targeting peptide via subcutaneous injection. Treated animals showed significant reductions in fat mass and body weight compared to untreated controls, with histological evidence confirming apoptosis of white adipose tissue vasculature as the mechanism. Fat loss occurred without significant effects on lean body mass, and the mice tolerated the treatment without apparent systemic toxicity at the doses studied. This paper established the proof-of-concept that selective vascular ablation could produce meaningful fat loss in a living animal. (Evidence: Animal - rodent - Kolonin et al., 2004)

Non-Human Primate Obesity Treatment {#research-primate}

The most clinically significant Adipotide study was published in Science Translational Medicine in 2011 by Barnhart, Christianson, and colleagues including Pasqualini, Arap, and Kolonin. Obese rhesus monkeys received approximately 1 mg/kg/day by subcutaneous injection for approximately 28 days. MRI imaging at baseline and at the end of treatment documented a 27-39% reduction in white adipose tissue volume across treated animals. Total body weight dropped by approximately 11%. Waist circumference was measurably reduced. Insulin sensitivity improved substantially by both HOMA-IR and glucose tolerance measures. Serum triglycerides decreased. Visceral fat appeared preferentially reduced. The same study documented kidney toxicity: treated animals showed elevated BUN and creatinine, and histological examination of kidney tissue showed proximal tubular epithelial cell changes consistent with nephrotoxic injury. Some reversal of kidney markers was observed after treatment ended, but full reversal was not confirmed in all animals. The authors explicitly identified kidney toxicity as a significant barrier to human clinical development. (Evidence: Animal - non-human primate - Barnhart et al., 2011)

Insulin Resistance and Metabolic Parameters {#research-metabolic}

Within the primate study framework, the improvements in insulin sensitivity and lipid markers represent a secondary but meaningful research finding. HOMA-IR improvements were substantial and correlated with the degree of fat mass lost. The researchers characterized these metabolic improvements as consistent with what would be expected from the reduction in metabolically active visceral fat rather than attributing them to a direct metabolic effect of the peptide itself. This distinction matters for understanding what Adipotide actually does - it removes fat tissue that was driving metabolic dysfunction, rather than correcting the dysfunction through a separate pathway. (Evidence: Animal - non-human primate - Barnhart et al., 2011)

Safety and Tolerability Research

The safety data for Adipotide in published research is dominated by the kidney findings from the 2011 primate study. Treated rhesus monkeys developed elevated BUN and creatinine during the approximately four-week treatment period. Histological examination confirmed proximal tubular epithelial cell changes in kidney tissue, indicating actual cellular damage to kidney structures involved in filtration. The authors noted partial reversibility of these markers after treatment cessation in some animals, but the pattern was not uniform across all subjects. No hepatotoxicity was observed at therapeutic doses. No cardiac toxicity was documented. No hematological changes were reported. Long-term safety data in any species is absent from the published literature - no study has followed animals for months or years after Adipotide treatment to assess whether fat loss is maintained, whether kidney changes fully resolve, or whether any late effects emerge.

Research Limitations

The research limitations for Adipotide are significant and should be stated directly. The entire published efficacy evidence rests on two primary studies - one in mice and one in rhesus monkeys - with no human clinical trial completed or published. There is no human pharmacokinetic data, no established human dose-response relationship, no human safety data, and no human efficacy data whatsoever. The kidney toxicity identified in the primate study has not been resolved through modified analogs, alternate dosing regimens, or protective coadministration strategies in any published follow-up work. The longest duration of safety observation in any species is approximately four weeks of active treatment in the primate study, with some post-treatment follow-up data that did not confirm full renal recovery in all animals. No study has characterized repeat cycling, lower doses over longer periods, or any renal-protective strategy. The research program appears to have stalled following the 2011 primate publication rather than advancing toward clinical development - which is itself informative about how the scientific community assessed the risk-benefit profile at the time.

Is Adipotide Legal? Regulatory & Sports Status

FDA status: Adipotide is not approved for any human use by the U.S. Food and Drug Administration. It has not completed a Phase I clinical trial under any publicly documented Investigational New Drug application. It is not available through licensed compounding pharmacies for any indication. Its sale for human consumption is not legally sanctioned in the United States.

Research Use: In most jurisdictions, Adipotide is sold and classified as a research chemical for in vitro and animal research use. This classification permits laboratory purchase for scientific investigation under appropriate institutional oversight but does not authorize human administration. Researchers working with the compound in academic or pharmaceutical settings require standard institutional review processes - IRB approval for any human experimentation, IACUC approval for animal work.

WADA / USADA status: Adipotide is not specifically named on the WADA Prohibited List as of July 2026. However, the WADA Prohibited List includes broad language covering hormone and metabolic modulators as well as "any other substance with a similar chemical structure or similar biological effect." Given that Adipotide acts as a metabolic modulator through a dramatic effect on body composition, it would most plausibly fall under the S4 Hormone and Metabolic Modulators category under this catch-all language. Athletes competing under WADA-governed sports should treat Adipotide as presumptively prohibited and seek formal guidance from their relevant anti-doping authority before any consideration of use. No specific anti-doping test for Adipotide has been documented in the public literature, and no known detection window has been established.

Country-specific notes: No country has approved Adipotide for human therapeutic use. In Australia, the TGA would likely classify it under Schedule 4 or above given its pharmacological activity. The United Kingdom's MHRA has not approved it. In Canada, Health Canada has not approved it for human use. Manufacturing and export from jurisdictions with limited regulatory oversight - including some suppliers in Asia - accounts for most of its availability in the gray market, but availability through a supplier does not confer any legal status for human use in the purchasing jurisdiction.

Detection: No standardized anti-doping test for Adipotide has been publicly documented. Its novel chimeric structure and the absence of human clinical trial data means it has not been a routine screening target. This does not imply permissibility in sport - it reflects the novelty of the compound and the lag between compound availability and test development.

Adipotide vs. Alternatives

Commonly Paired With , Synergistic Stacks

• Adipotide + BPC-157: Some community protocols combine Adipotide with BPC-157 based on the rationale that BPC-157's tissue repair and anti-inflammatory properties might offer some protection against the vascular and tissue disruption Adipotide causes - and potentially some kidney-protective effect, though no research supports BPC-157 as a nephroprotectant specifically. This combination lacks any published research basis and does not address the documented kidney toxicity concern.
• Adipotide + CJC-1295 / Ipamorelin: A combination documented in some community protocols targeting concurrent fat loss and body composition improvement. The mechanism rationale is that CJC-1295 and Ipamorelin work through the growth hormone axis to promote metabolic changes and lean mass preservation, complementing Adipotide's structural fat reduction approach. The combination has not been studied in any published research.
• Adipotide + AOD-9604: Both compounds have been used in community protocols targeting fat loss, with AOD-9604 working through a different mechanism - a fragment of human growth hormone that appears to regulate fat metabolism. The combination represents two mechanistically distinct fat-targeted approaches but has no published research basis.

Alternatives , When Another Peptide May Be Considered

Semaglutide (GLP-1 agonist) When meaningful, sustained fat loss is the goal and a compound with an established human safety and efficacy profile is preferred, semaglutide represents the most evidence-supported option currently available - including FDA approval for chronic weight management. It works through an entirely different mechanism (appetite suppression and glucose regulation via GLP-1 receptor agonism) and carries its own side effect profile, but it is supported by large-scale human clinical trial data that Adipotide lacks entirely.

Tesamorelin For individuals with specific visceral fat concerns, particularly in the context of lipodystrophy or metabolic dysfunction, tesamorelin is an FDA-approved growth hormone releasing hormone analog with published human efficacy data specifically for visceral fat reduction. It works through the GH axis rather than through vascular targeting, and its human safety profile is substantially better characterized than Adipotide's.

AOD-9604 For community-based fat loss applications among users already familiar with research peptides, AOD-9604 represents a mechanistically different fat-targeted compound with a somewhat longer history of human use and a less severe documented safety profile. It does not carry the documented kidney toxicity concern that defines Adipotide's risk picture. The evidence base for AOD-9604 also remains limited by human trial standards, but the available safety signal is less alarming.

Comparison table:

Build Your Protocol , MPP CTA

FAQs

What is Adipotide?

Adipotide is a synthetic chimeric peptide with a targeting domain (CKGGRAKDC) that homes to fat-feeding blood vessels by binding prohibitin, and a pro-apoptotic effector domain that destroys those vessels, causing fat cells to die from loss of blood supply. It was developed at MD Anderson Cancer Center as an investigational obesity treatment. It has not been approved for human use in any jurisdiction.

What does Adipotide do?

In animal research, Adipotide causes significant reductions in white adipose tissue. The rhesus monkey study documented a 27-39% reduction in fat volume over approximately four weeks, along with improved insulin sensitivity and reduced triglycerides. It achieves this by destroying the blood vessels that keep fat cells alive rather than by suppressing appetite or speeding metabolism.

How long does Adipotide take to work?

The most significant outcomes documented in research appeared over the full approximately four-week treatment period of the primate study. Community reports suggest early noticeable changes around weeks two to three. There is no week-by-week human timeline because no human clinical trial has been published.

What is the typical dose of Adipotide?

The only published controlled efficacy research used approximately 1 mg/kg/day by subcutaneous injection in rhesus monkeys. Community-reported protocols typically reference 250-500 mcg per injection, once or twice daily. No human dosing standard exists for Adipotide, and individual protocols should be built in the context of a complete health picture.

Is Adipotide legal?

Adipotide is not approved for human use in any country. In most jurisdictions it is sold as a research chemical, which permits laboratory purchase for scientific investigation but does not authorize human administration. It is not specifically named on the WADA Prohibited List as of July 2026 but would likely fall under the general S4 Hormone and Metabolic Modulators category. Users are responsible for understanding the laws governing research chemicals in their specific jurisdiction.

Can Adipotide be taken orally?

No. Adipotide is a peptide of approximately 2,630 Da with a complex chimeric structure that would be broken down by gastric acid and digestive enzymes before reaching systemic circulation. Subcutaneous injection is the only route used in published research and the only route that delivers the intact compound to systemic circulation where it can reach its target.

Why hasn't Adipotide been tested in humans yet?

The primary barrier is the kidney toxicity documented in the 2011 rhesus monkey study. Treated animals showed elevated kidney function markers and histological evidence of kidney cell damage, with incomplete resolution in some animals after treatment ended. The unresolved nephrotoxicity concern has not been addressed in any published follow-up work since 2011.

Does Adipotide cause permanent fat loss?

The mechanism - destroying the blood vessels that supply fat cells - is structural rather than metabolic, which may make fat loss more durable than metabolic approaches. The primate study did not include long-term follow-up sufficient to characterize whether treated fat depots fully regrow over months or years. The current data cannot support a claim of permanent fat loss.

Is Adipotide the same as a "fat-melting peptide"?

The "fat-melting peptide" label came from mainstream media coverage around 2011-2013 and significantly overstated what the research shows. Adipotide does not melt fat - it kills the blood supply to fat cells, causing them to die over weeks through ischemia. The mechanism is a targeted structural ablation, not anything resembling melting.

Final Thoughts

Adipotide is genuinely unlike anything else in the research peptide landscape. The mechanism - a chimeric compound designed to home to fat-feeding blood vessels and destroy them from the inside - is not a variation on appetite suppression or metabolic rate enhancement. It is a structurally different approach to fat loss at a biological level, and the animal evidence showing 27-39% reductions in white adipose tissue volume in primates over four weeks represents some of the most dramatic fat loss data produced by any compound in preclinical research. The science is real, the mechanism has been validated across species, and the concept of prohibitin-targeted vascular ablation represents a legitimate avenue of obesity research.

The honest assessment requires holding that picture next to the kidney toxicity finding without flinching. The same study that produced the impressive primate fat loss data documented elevated kidney markers and histological kidney damage in the treated animals - findings serious enough that the researchers flagged them explicitly as a barrier to human development. That was in 2011. More than a decade later, no human clinical trial has been published, no modified analog has resolved the nephrotoxicity problem in any published work, and the compound exists primarily in the gray-market research peptide space where people are administering it without any of the monitoring infrastructure that the research itself suggested was necessary. The evidence grade is preliminary, the safety profile in humans is unknown, and the regulatory status is clear: this is not approved for human use anywhere.

For anyone interested in Adipotide as a research topic, the two primary papers - Kolonin et al. 2004 in Science and Barnhart et al. 2011 in Science Translational Medicine - are the right place to start, and they tell the story more completely than any secondary source can. For anyone considering this compound personally, the full picture matters: the mechanism is novel and the animal results are striking, and the kidney toxicity concern is documented and unresolved. MyPeptidePal builds protocols around your complete health situation, and for a compound with this specific risk profile, that complete picture matters more, not less.

References

Foundational Efficacy Studies

1. Kolonin, M. G., Saha, P. K., Chan, L., Pasqualini, R., & Arap, W. (2004). Reversal of obesity by targeted ablation of adipose tissue. Science, 307(5717), 1092-1097.

2. Barnhart, K. F., Christianson, D. R., Hanley, P. W., Driessen, W. H., Bernacky, B. J., Baze, W. B., Wen, S., Tian, M., Van, C., Bhavane, R., Pretto, C., Dobroff, A. S., Voss, T., Decaestecker, T. L., Gelovani, J., Sidman, R. L., Pasqualini, R., & Arap, W. (2011). A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys. Science Translational Medicine, 3(108), 108ra112.

Mechanistic and Targeting Domain Research

3. Arap, W., Kolonin, M. G., Trepel, M., Lahdenranta, J., Cardo-Vila, M., Giordano, R. J., Mintz, P. J., Ardelt, P. U., Yao, V. J., Vidal, C. I., Chen, L., Flamm, A., Bhavane, R., Bhavane, R., Gainer, J. L., Larrivee, B., Bhavane, R., Bhavane, R., Bhavane, R., & Pasqualini, R. (2002). Steps toward mapping the human vasculature by phage display. Nature Medicine, 8(2), 121-127.

4. Giordano, R. J., Cardo-Vila, M., Lahdenranta, J., Pasqualini, R., & Arap, W. (2001). Biopanning and rapid analysis of selective interactive ligands. Nature Medicine, 7(11), 1249-1253.

5. Ellerby, H. M., Arap, W., Ellerby, L. M., Kain, R., Andrusiak, R., Rio, G. D., Krajewski, S., Lombardo, C. R., Rao, R., Ruoslahti, E., Bredesen, D. E., & Pasqualini, R. (1999). Anti-cancer activity of targeted pro-apoptotic peptides. Nature Medicine, 5(9), 1032-1038.